Haemostatic Abnormalities Persist Despite Glycaemic Improvement by Insulin Therapy in Lean Type 2 Diabetic Patients

Summary

Diabetes mellitus is associated with disturbances of the haemostatic system, which might contribute to the development of diabetic vascular disease. We investigated the effect of metabolic improvement by insulin therapy on the haemostatic system in 61 patients with type 2 diabetes mellitus and secondaxy sulfunyluiea failure compared with 45 healthy control subjects matched for age, sex and BMI. Median age was 65, median diabetes duration 10 years. Median HbA_1c (10%) and fructosamine (4.0 mM) levels were elevated before induction of therapy and decreased significantly within 6 months of insulin treatment to 7.5% and 3.0 mM, respectively (p <0.0001). Compared with control subjects, median plasma levels of fibrinogen (317 vs 286 mg/dl), coagulation factor VII activity (1.1 vs 0.89 U/1), von Willebrand factor (1.6 vs 1.3 U/1), D-dimer (105 vs 86 jug/1), protein C:Ag (1.24 vs 0.95 U/1), total protein S:Ag (1.15 vs 0.91 U/1), and antithrombin III activity (1.17 vs 1.08 U/1) were significantly elevated. Levels of free protein S were not different from control values. No significant decline of coagulation parameters could be recorded during insulin therapy. Patients with diabetic vasculopathy had higher levels of D-dimer than those without (133 vs 76 μg/1 before, 109 vs 88 μg/1 during therapy), whereas the other haemostatic parameters were not different. Our data indicate a significant activation of the coagulation system in diabetic patients with secondary failure to sulfonylurea drugs, with signs of a prethrombotic state and endothelial cell disturbance. Induction of insulin therapy results in a significant improvement of glycaemic and lipid metabolism, but the persisting enhanced activity state of the haemostatic system might contribute to the increased cardiovascular mortality of type 2 diabetic patients.

• References

• 1 Cciiellu A. Cuugululiun aclivuLion in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabctologia 1993; 36: 1119-25
• 2 Kwaan HC. Changes in blood coagulation, platelet function and plasminogen plasmin system in diabetes. Diabetes 1992; 41 Suppl (Suppl. 02) 32-5
• 3 Schernthaner G, Vukovich T, Gisinger C. Anomalies de l’hemostase au cours du diabete sucre. Journ Annu Diabetol Hotel Dieu 1991; 91-107
• 4 Knöbl P, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M, Schernthaner G. Thrombogenic factors are related to urinary albumin excretion rate in Type 1 and Type 2 diabetic patients. Diabetologia 1993; 36: 1045-50
• 5 Lee P, Jenkins A, Bourke C, Santamaria J, Paton C, Janus E, Best J. Prothrombotic and antithrombotic factors are elevated in patients with Type 1 diabetes complicated by microalbuminuria. Diab Med 1993; 10: 122-8
• 6 Fuller JH, Keen H, Jarrett RJ, Orner T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes and its complications. Brit Med J 1979; 2: 964-6
• 7 Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-6
• 8 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7
• 9 Morrish NH, Stavens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort if the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia 1990; 33: 538-41
• 10 Morrish NJ, Stavens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort if the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia 1990; 33: 542-8
• 11 Uusitupa MU, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. 5 year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in noninsulin-dependent diabetic and nondiabetic subjects. Circulation 1990; 82: 27-36
• 12 Jensen T. Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy. Brit Med J 1989; 298: 27-8
• 13 Borkenstein MH, Muntean WE. Elevated factor VIII activity and factor VIII related antigen in diabetic children without vascular disease. Diabetes 1982; 31: 1006-9
• 14 Vukovich TC, Schemthaner G, Knobl PN, Hay U. The effect of nearnormoglycaemic control on plasma factor VIII/von Willebrand factor and fibrin degradation products in insulin dependent diabetic patients. J Clin Endocrinol Metab 1989; 69: 84-9
• 15 Vukovich T, Schemthaner G. Decreased protein C levels in patients with insulin dependent type 1 diabetes mellitus. Diabetes 1986; 35: 617-9
• 16 Vigano S, Mannucci PM, D’Angelo A, Gelfi C, Gensini GF, Rostagno C, Neri Serneri GG. Protein C Antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost 1984; 52: 263-6
• 17 Takahashi H, Tatewaki W, Wada K, Shibata A. Plasma protein S in disseminated intravascular coagulation, liver disease, collagen disease, diabetes mellitus, and under oral anticoagulant therapy. Clin Chim Acta 1989; 182: 195-208
• 18 Oida K, Takai H, Maeda H, Takahashi S, Tamai T, Nakai T, Miyabo S, Ishii H. Plasma thrombomodulin concentration in diabetes mellitus. Diab Res Clin Pract 1990; 10: 193-6
• 19 Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37/2: 269-72
• 20 Takahashi H, Seiki I, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 41: 32-9
• 21 Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diab Med 1991; 8: 898-905
• 22 Van Wersch JW, Westerhuis LW, Venekamp WJ. Glycometabolic control and fibrinolysis in diabetic patients. Haemostasis 1990; 20: 241-50
• 23 Speiser W, Speiser P, Minar E, Korninger C, Niessner H, Huber K, Schemthaner G, Ehringer H, Lechner K. Activation of coagulation and fibrinolysis in patients with arteriosclerosis. Thromb Res 1990; 59: 77-88
• 24 Marongiu F, Conti M, Mameli G, Sorano GG, Cossu E, Cilillo R, Balestrieri A. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?. Thromb Res 1990; 58: 91-9
• 25 Garcia-Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia Avello A. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-9
• 26 Takahashi H, Tsuda A, Tatewaki W, Wada K, Niwano H, Shibata A. Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by plasma levels of thrombin – antithrombin III complex and plasmin – alpha 2 plasmin inhibitor complex. Thromb Res 1989; 55: 727-35
• 27 Simonson DC. Hyperinsulinaemia and its sequelae. Horm Metab Res Suppl 1990; 22: 17-25
• 28 Robertson DA, Hale PJ, Nattrass M. Macrovascular disease and hyperinsulinaemia. Baillieres Clin Endocrinol Metab 1988; 2: 407-24
• 29 Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinaemia. Metabolism 1988; 37 2 Suppl (Suppl. 01) 1-9
• 30 Schemthaner G, Vukovich T, Knobl P, Hay U, Müller M. The effect of near normoglycaemic control on plasma levels of coagulation factor VII and the anticoagulants protein C and S in insulin dependent diabetic patients. Brit J Haematol 1989; 73: 356-9
• 31 Knobl PN, Fischer P, Kaliman JF, Vukovich TC. Plasma levels of protein C and protein S in patients with vasculopathy. Thromb Res 1987; 45: 857-63
• 32 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol Leipzig 1957; 17: 237-40
• 33 SAS Users Guide. SAS Institute, Statistical Analysis System. Cary, North Carolina: 1985. ISBN 0-917382-36-6
• 34 Kudlacek S, Schemthaner G. The effect of insulin treatment on HbAlc, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res 1992; 24: 455-500
• 35 Schmitz A, Ingerslev J. Haemostatic measurements in Type 2 (non-insulin-dependent) diabetic patients with microalbuminurea. Diabetic Med 1990; 7: 521-5
• 36 Jumming L, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1988; 61: 588-602
• 37 Hornsby WG, Boggess KA, Lyons TJ, Barnwell WH, Lazarchick J, Colwell JA. Haemostatic alterations with exercise conditioning in NIDDM. Diabetes Care 1990; 13: 87-92
• 38 Jennings AM, Ford I, Murdoch S, Greaves M, Preston FE, Ward JD. The Effects of Diet and Insulin Therapy on Coagulation Factor VII, Blood Viscosity, and Platelet Release Proteins in Diabetic Patients with Secondary Sulfonylurea Failure. Diab Med 1990; 8: 346-53
• 39 Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW. Effect of treatment of hyperlipidaemia on haemostatic variables. Brit Med J 1980; 281: 973-4
• 40 Vukovich T, Proidl S, Knöbl P, Teufelsbauer H, Schnack C, Schemthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-6
• 41 Sinzinger H, Virgolini I. Nuclear medicine and atherosclerosis. Europ J Nucl Med 1990; 17: 160-78